Cathepsin K inhibition-induced mitochondrial ROS enhances sensitivity of cancer cells to anti-cancer drugs through USP27x-mediated Bim protein stabilization

[1]  J. Bae,et al.  Alleviation of Ultraviolet B-Induced Photoaging by 7-MEGATM 500 in Hairless Mouse Skin , 2019, Toxicological research.

[2]  Antonio García de Herreros,et al.  TGFβ-Activated USP27X Deubiquitinase Regulates Cell Migration and Chemoresistance via Stabilization of Snail1. , 2018, Cancer research.

[3]  Cheolju Lee,et al.  K6 linked polyubiquitylation of FADD by CHIP prevents death inducing signaling complex formation suppressing cell death , 2018, Oncogene.

[4]  S. Woo,et al.  Z-FL-COCHO, a cathepsin S inhibitor, enhances oxaliplatin-induced apoptosis through upregulation of Bim expression. , 2018, Biochemical and Biophysical Research Communications - BBRC.

[5]  Lei Shi,et al.  USP27-mediated Cyclin E stabilization drives cell cycle progression and hepatocellular tumorigenesis , 2018, Oncogene.

[6]  A. Harris,et al.  RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition , 2018, PloS one.

[7]  J. Ježek,et al.  Reactive Oxygen Species and Mitochondrial Dynamics: The Yin and Yang of Mitochondrial Dysfunction and Cancer Progression , 2018, Antioxidants.

[8]  S. Woo,et al.  Up-regulation of 5-lipoxygenase by inhibition of cathepsin G enhances TRAIL-induced apoptosis through down-regulation of survivin , 2017, Oncotarget.

[9]  H. McBride,et al.  mTOR Controls Mitochondrial Dynamics and Cell Survival via MTFP1. , 2017, Molecular cell.

[10]  G. Yoon,et al.  Inhibition of Cathepsin S Induces Mitochondrial ROS That Sensitizes TRAIL-Mediated Apoptosis Through p53-Mediated Downregulation of Bcl-2 and c-FLIP. , 2017, Antioxidants & redox signaling.

[11]  R. Bjerkvig,et al.  Cathepsin L silencing increases As2O3 toxicity in malignantly transformed pilocytic astrocytoma MPA58 cells by activating caspases 3/7 , 2017, Experimental cell research.

[12]  J. Gécz,et al.  USP9X deubiquitylating enzyme maintains RAPTOR protein levels, mTORC1 signalling and proliferation in neural progenitors , 2017, Scientific Reports.

[13]  Mu-Kuan Chen,et al.  Inhibition of cathepsin S confers sensitivity to methyl protodioscin in oral cancer cells via activation of p38 MAPK/JNK signaling pathways , 2017, Scientific Reports.

[14]  M. Hall,et al.  mTOR Signaling Confers Resistance to Targeted Cancer Drugs. , 2016, Trends in cancer.

[15]  V. Grünwald,et al.  Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. , 2016, Cancer treatment reviews.

[16]  S. Woo,et al.  YM155 sensitizes TRAIL-induced apoptosis through cathepsin S-dependent down-regulation of Mcl-1 and NF-κB-mediated down-regulation of c-FLIP expression in human renal carcinoma Caki cells , 2016, Oncotarget.

[17]  J. Dengjel,et al.  The deubiquitinase Usp27x stabilizes the BH3‐only protein Bim and enhances apoptosis , 2016, EMBO reports.

[18]  G. Mortier,et al.  Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors , 2016, British Journal of Cancer.

[19]  Caihong Tan,et al.  Knockdown of Cathepsin L promotes radiosensitivity of glioma stem cells both in vivo and in vitro. , 2016, Cancer letters.

[20]  C. Van Noorden,et al.  Complexity of cancer protease biology: Cathepsin K expression and function in cancer progression. , 2015, Seminars in cancer biology.

[21]  X. Mao,et al.  SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathway , 2015, Scientific Reports.

[22]  Zhong-Qin Liang,et al.  Cathepsin L suppression increases the radiosensitivity of human glioma U251 cells via G2/M cell cycle arrest and DNA damage , 2015, Acta Pharmacologica Sinica.

[23]  Kakajan Komurov,et al.  Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma. , 2014, Cancer research.

[24]  Y. Yoo,et al.  Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression , 2014, Cell Death and Disease.

[25]  Han-dong Wang,et al.  Inhibition of cathepsin S induces autophagy and apoptosis in human glioblastoma cell lines through ROS-mediated PI3K/AKT/mTOR/p70S6K and JNK signaling pathways. , 2014, Toxicology letters.

[26]  C. Schnell,et al.  Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT , 2014, Clinical Cancer Research.

[27]  A. Letai,et al.  APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction. , 2014, Developmental cell.

[28]  David A. Scott,et al.  Genome engineering using the CRISPR-Cas9 system , 2013, Nature Protocols.

[29]  R. Bjerkvig,et al.  Cathepsin L silencing enhances arsenic trioxide mediated in vitro cytotoxicity and apoptosis in glioblastoma U87MG spheroids. , 2013, Experimental cell research.

[30]  K. Flaherty,et al.  TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma , 2013, Science Translational Medicine.

[31]  R. Mason,et al.  Inhibitors of cathepsins B and L induce autophagy and cell death in neuroblastoma cells , 2013, Investigational New Drugs.

[32]  A. Feldman,et al.  Ubiquitin Hydrolase UCH-L1 Destabilizes mTOR Complex 1 by Antagonizing DDB1-CUL4-Mediated Ubiquitination of Raptor , 2013, Molecular and Cellular Biology.

[33]  J. S. Ahn,et al.  Cathepsin D inhibits oxidative stress-induced cell death via activation of autophagy in cancer cells. , 2012, Cancer letters.

[34]  F. Essmann,et al.  Deubiquitinase USP9x confers radioresistance through stabilization of Mcl-1. , 2012, Neoplasia.

[35]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[36]  Sarat Chandarlapaty,et al.  mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. , 2011, Cancer discovery.

[37]  S. Cremers,et al.  Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis , 2011, Nature Reviews Rheumatology.

[38]  P. Saftig,et al.  Cathepsin K deficiency in mice induces structural and metabolic changes in the central nervous system that are associated with learning and memory deficits , 2011, BMC Neuroscience.

[39]  Philip R. Gafken,et al.  Identification of a Novel Bcl-2-interacting Mediator of Cell Death (Bim) E3 Ligase, Tripartite Motif-containing Protein 2 (TRIM2), and Its Role in Rapid Ischemic Tolerance-induced Neuroprotection* , 2011, The Journal of Biological Chemistry.

[40]  R. Sobel,et al.  Aberrant mitochondrial fission in neurons induced by protein kinase Cδ under oxidative stress conditions in vivo , 2011, Molecular biology of the cell.

[41]  J. Tschopp,et al.  A role for mitochondria in NLRP3 inflammasome activation , 2011, Nature.

[42]  L. Holsinger,et al.  Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model. , 2010, Biochimie.

[43]  T. M. Rünger,et al.  Expression and regulation of cathepsin K in skin fibroblasts , 2009, Experimental dermatology.

[44]  B. Bogerts,et al.  Cathepsin K generates enkephalin from β-endorphin: A new mechanism with possible relevance for schizophrenia , 2009, Neurochemistry International.

[45]  Gerard Manning,et al.  TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. , 2009, Cancer research.

[46]  Michael S. Cohen,et al.  betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. , 2009, Molecular cell.

[47]  P. Bernardi,et al.  Dephosphorylation by calcineurin regulates translocation of Drp1 to mitochondria , 2008, Proceedings of the National Academy of Sciences.

[48]  T. M. Rünger,et al.  Cathepsin K in melanoma invasion. , 2008, The Journal of investigative dermatology.

[49]  K. Brix,et al.  Cysteine cathepsins: cellular roadmap to different functions. , 2008, Biochimie.

[50]  V. Mootha,et al.  mTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex , 2007, Nature.

[51]  D. Hanahan,et al.  Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. , 2007, Cancer research.

[52]  C. Blackstone,et al.  Cyclic AMP-dependent Protein Kinase Phosphorylation of Drp1 Regulates Its GTPase Activity and Mitochondrial Morphology* , 2007, Journal of Biological Chemistry.

[53]  R. Roth,et al.  PRAS40 Regulates mTORC1 Kinase Activity by Functioning as a Direct Inhibitor of Substrate Binding* , 2007, Journal of Biological Chemistry.

[54]  J. P. McCoy,et al.  The Mammalian Target of Rapamycin (mTOR) Pathway Regulates Mitochondrial Oxygen Consumption and Oxidative Capacity* , 2006, Journal of Biological Chemistry.

[55]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[56]  K. Hruska,et al.  Akt1/Akt2 and Mammalian Target of Rapamycin/Bim Play Critical Roles in Osteoclast Differentiation and Survival, Respectively, Whereas Akt Is Dispensable for Cell Survival in Isolated Osteoclast Precursors* , 2005, Journal of Biological Chemistry.

[57]  E. Vuorio,et al.  Up regulation of cathepsin K expression in articular chondrocytes in a transgenic mouse model for osteoarthritis , 2004, Annals of the rheumatic diseases.

[58]  J. Avruch,et al.  Dissociation of raptor from mTOR is a mechanism of rapamycin‐induced inhibition of mTOR function , 2004, Genes to cells : devoted to molecular & cellular mechanisms.

[59]  J. Avruch,et al.  The Mammalian Target of Rapamycin (mTOR) Partner, Raptor, Binds the mTOR Substrates p70 S6 Kinase and 4E-BP1 through Their TOR Signaling (TOS) Motif* , 2003, The Journal of Biological Chemistry.